Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12459117 | 1.00 | CYP3A4 (0.32) | CYP3A4 | |
| SCHEMBL29702769 | 1.00 | CYP3A4 (0.32) | CYP3A4 | |
| SCHEMBL12516833 | 0.87 | — | — | |
| SCHEMBL19361211 | 0.84 | CYP3A4 (0.30) | CYP3A4 | |
| SCHEMBL12459505 | 0.77 | CYP3A4 (0.31) | CYP3A4 | |
| SCHEMBL29655269 | 0.77 | CYP3A4 (0.31) | CYP3A4 | |
| SCHEMBL13822287 | 0.77 | CYP3A4 (0.31) | CYP3A4 | |
| SCHEMBL12459119 | 0.73 | CYP3A4 (0.32) | CYP3A4 | |
| Isozaluzanin C SCHEMBL24453721 | 0.70 | PKM (0.40) | CYP3A4 | |
| Isozaluzanin C SCHEMBL17214374 | 0.70 | PKM (0.40) | CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12403171-B2 | Plant extract highly concentrated in safranal, production method and uses thereof | ACTIV'INSIDE (FR) | 2025-09-02 | — | — | US | claimed |
| EP-3490575-B2 | PLANT EXTRACT HIGHLY CONCENTRATED IN SAFRANAL, PRODUCTION METHOD AND USES THEREOF | ACTIVINSIDE (FR) | 2025-04-16 | — | — | EP | claimed |
| US-20230165927-A1 | PLANT EXTRACT HIGHLY CONCENTRATED IN SAFRANAL, PRODUCTION METHOD AND USES THEREOF | ACTIV'INSIDE (FR) | 2023-06-01 | — | — | US | claimed |
| US-11590193-B2 | Plant extract highly concentrated in safranal, production method and uses thereof | ACTIV'INSIDE (FR) | 2023-02-28 | — | — | US | claimed |
| EP-4115896-A1 | PLANT EXTRACT WITH A HIGH CONCENTRATION OF SAFRANAL, METHOD FOR OBTAINING SAME AND USES THEREOF | Activ'inside (FR) | 2023-01-11 | — | — | EP | claimed |
| EP-3490575-B1 | PLANT EXTRACT HIGHLY CONCENTRATED IN SAFRANAL, PRODUCTION METHOD AND USES THEREOF | ACTIVINSIDE (FR) | 2022-05-04 | — | — | EP | claimed |
| EP-3030226-B1 | DELIVERY SYSTEM FOR ACTIVE AGENTS | KIMBERLY CLARK CO (US) | 2025-09-03 | — | — | EP | disclosed |
| US-12403171-B2 | Plant extract highly concentrated in safranal, production method and uses thereof | ACTIV'INSIDE (FR) | 2025-09-02 | — | — | US | disclosed |
| US-20250161182-A1 | ANTIMICROBIAL COMPOSITIONS | BIO-ACTIVES SYNERGIO LTD (IL) | 2025-05-22 | — | — | US | disclosed |
| EP-3490575-B2 | PLANT EXTRACT HIGHLY CONCENTRATED IN SAFRANAL, PRODUCTION METHOD AND USES THEREOF | ACTIVINSIDE (FR) | 2025-04-16 | — | — | EP | disclosed |
| US-20250114420-A1 | ANTIMICROBIAL NATURAL COMPOSITIONS | BIO-ACTIVES SYNERGIO LTD (IL) | 2025-04-10 | — | — | US | disclosed |
| EP-4469037-A1 | ANTIMICROBIAL COMPOSITIONS | Bio-Actives Synergio Ltd (IL) | 2024-12-04 | — | — | EP | disclosed |
| EP-4469071-A1 | ANTIMICROBIAL NATURAL COMPOSITIONS | Bio-Actives Synergio Ltd (IL) | 2024-12-04 | — | — | EP | disclosed |
| US-20230165927-A1 | PLANT EXTRACT HIGHLY CONCENTRATED IN SAFRANAL, PRODUCTION METHOD AND USES THEREOF | ACTIV'INSIDE (FR) | 2023-06-01 | — | — | US | disclosed |
| CN-115916229-A | Composition comprising safranal and a probiotic | 活力因赛德公司 | 2023-04-04 | — | — | CN | disclosed |
| EP-4153199-A1 | COMPOSITION COMPRISING SAFRANAL AND PROBIOTICS | Activ'inside (FR) | 2023-03-29 | — | — | EP | disclosed |
| US-11590193-B2 | Plant extract highly concentrated in safranal, production method and uses thereof | ACTIV'INSIDE (FR) | 2023-02-28 | — | — | US | disclosed |
| EP-4135676-A1 | COMPOSITION FOR IMPROVING COGNITIVE FUNCTION | Activ'inside (FR) | 2023-02-22 | — | — | EP | disclosed |
| EP-4115896-A1 | PLANT EXTRACT WITH A HIGH CONCENTRATION OF SAFRANAL, METHOD FOR OBTAINING SAME AND USES THEREOF | Activ'inside (FR) | 2023-01-11 | — | — | EP | disclosed |
| EP-3490575-B1 | PLANT EXTRACT HIGHLY CONCENTRATED IN SAFRANAL, PRODUCTION METHOD AND USES THEREOF | ACTIVINSIDE (FR) | 2022-05-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250161182-A1 | ANTIMICROBIAL COMPOSITIONS | NOD2, PYCARD, CLPP | CYP3A4 1077/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.